APrevent signed the distribution agreement in Lithuania


APrevent announced on 7TH December that APrevent and Labostera signed the distribution agreement for APrevent® VOIS in Lithuania. We are going to provide patients with glottic insufficiency/unilateral vocal fold paralysis an innovative, safe and effective surgical treatment.

Labostera was founded in year 2005, they are experienced in ENT surgical products including surgical voice prosthesis, other surgical, ENT implants and equipment. APrevent cooperates with Labostera to expand market and sell APrevent® VOIS to Lithuania.


APrevent® VOIS:



APrevent® VOIS is characterized by its unique design for medialization thyroplasty. The goal is to get optimized results with reduced complications and revision rates. It is the first implant in the market that can be adjusted both intra- and postoperatively. Follow up procedures can be easily performed. The particular shape and unique design of the implant enables a precise adjustment of VOIS , improving voice quality, swallowing and preventing complications from glottic insufficiency. The implant materials are biocompatible medical grade silicone and titanium and can be implanted through a minimal invasive and standardized procedure, the latteralleviating pain and shortening of recovery time. Postoperative implant adjustments make it possible to optimize individual needs without revision surgery.